Phase 3 Ankylosing Spondylitis Trial, Recruiting NCT06000956 Sponsor: Tasly Pharmaceutical Group Co., Ltd Condition: Ankylosing Spondylitis
Back to Ankylosing Spondylitis

Phase 3 Ankylosing Spondylitis Trial, Recruiting

NCT06000956
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 65 years old (inclusive), of any gender
  • You have been diagnosed with axial osteoarthritis (a type of spinal joint disease) based on 2009 ASAS guidelines, and your condition is currently active, shown by specific scores on two pain and disease activity rating scales
  • Your condition matches a Traditional Chinese Medicine pattern described as "kidney yang deficiency and blood stasis obstruction syndrome" (confirm with trial site)
  • A CT scan shows your sacroiliac joint (where your spine meets your pelvis) is affected at a mild to moderate level (grades I–II)
  • You have tested positive for a genetic marker called HLA-B27
  • Your blood tests show raised inflammation levels (CRP and/or ESR)
  • You are willing to take part voluntarily and sign a consent form

Who may not be able to join:

  • You have taken anti-inflammatory painkillers (NSAIDs) in the 2 weeks before joining
  • You have taken certain Chinese herbal medicines, disease-modifying drugs (such as methotrexate or sulfasalazine), opioid painkillers, JAK inhibitor drugs, or steroid tablets in the 4 weeks before joining
  • You have had surgery on your spine or joints in the 8 weeks before joining
  • You have received biologic medicines used for spinal arthritis in the 12 weeks before joining
  • You have had steroid injections into a joint, the spine, or the area around the spine in the 6 months before joining
  • Your CT scan shows the sacroiliac joint space has completely disappeared or your spine has become fully rigid
  • You have been diagnosed with another immune system or rheumatic disease, such as active ulcerative colitis, psoriasis, or uveitis
  • You are planning to try to have a child within the next six months
  • You are currently pregnant or breastfeeding
  • You have a known or suspected problem with misuse of drugs, substances, or alcohol
  • You have taken part in another clinical trial in the past 3 months or are currently in one
  • You have serious heart, liver, kidney, brain, or mental health conditions that may affect your ability to give consent or to report side effects
  • Your liver or kidney function blood tests are outside the normal range
  • The trial researchers consider you unsuitable for any other reason (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 022-27432680

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Tasly Pharmaceutical Group Co., Ltd
Registry
ClinicalTrials.gov
Start date
11 September 2023
Est. completion
1 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

ASAS20

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov